User login
Key clinical point: Addition of an antiangiogenic drug to second-line therapy may boost overall survival (OS) and progression-free survival (PFS) in patients with advanced non–small-cell lung cancer (NSCLC).
Major finding: The antiangiogenic drug plus second-line therapy vs. second-line therapy alone improved OS by 7% (hazard ratio [HR] 0.93; P = .005) and PFS by 20% (HR 0.80; P < .0001). The antiangiogenic group had a greater frequency of grade ≥3 toxicity.
Study details: The findings come from a patient data meta-analysis of 16 randomized controlled trials including 8629 participants.
Disclosures: The study did not receive any external funding. R Herbst, M Reck, EB Garon, GV Scagliotti, R Ramlau, N Hanna, J Vansteenkiste, K Yoh, HJM Groen, JV Heymach, and RS Heist were authors for some of the individual trials included in the meta-analysis. The other authors declared no conflicts of interest.
Source: Remon J et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022;166:112-125 (Mar 11). Doi: 10.1016/j.ejca.2022.02.002
Key clinical point: Addition of an antiangiogenic drug to second-line therapy may boost overall survival (OS) and progression-free survival (PFS) in patients with advanced non–small-cell lung cancer (NSCLC).
Major finding: The antiangiogenic drug plus second-line therapy vs. second-line therapy alone improved OS by 7% (hazard ratio [HR] 0.93; P = .005) and PFS by 20% (HR 0.80; P < .0001). The antiangiogenic group had a greater frequency of grade ≥3 toxicity.
Study details: The findings come from a patient data meta-analysis of 16 randomized controlled trials including 8629 participants.
Disclosures: The study did not receive any external funding. R Herbst, M Reck, EB Garon, GV Scagliotti, R Ramlau, N Hanna, J Vansteenkiste, K Yoh, HJM Groen, JV Heymach, and RS Heist were authors for some of the individual trials included in the meta-analysis. The other authors declared no conflicts of interest.
Source: Remon J et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022;166:112-125 (Mar 11). Doi: 10.1016/j.ejca.2022.02.002
Key clinical point: Addition of an antiangiogenic drug to second-line therapy may boost overall survival (OS) and progression-free survival (PFS) in patients with advanced non–small-cell lung cancer (NSCLC).
Major finding: The antiangiogenic drug plus second-line therapy vs. second-line therapy alone improved OS by 7% (hazard ratio [HR] 0.93; P = .005) and PFS by 20% (HR 0.80; P < .0001). The antiangiogenic group had a greater frequency of grade ≥3 toxicity.
Study details: The findings come from a patient data meta-analysis of 16 randomized controlled trials including 8629 participants.
Disclosures: The study did not receive any external funding. R Herbst, M Reck, EB Garon, GV Scagliotti, R Ramlau, N Hanna, J Vansteenkiste, K Yoh, HJM Groen, JV Heymach, and RS Heist were authors for some of the individual trials included in the meta-analysis. The other authors declared no conflicts of interest.
Source: Remon J et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022;166:112-125 (Mar 11). Doi: 10.1016/j.ejca.2022.02.002